1. Field of the Invention:
The present invention relates to the field of medical devices and, in particular, to devices for delivery of medicament. More particularly, the present invention relates to a cartridge system for delivery of insulin or other medicament.
2. Description of the Related Art:
Diabetes is a disease caused by the body's failure to produce adequate insulin or the cell's failure to respond to insulin resulting in high levels of sugar in the blood. If left untreated, diabetes can cause numerous complications. Typically, treatment for diabetes required both repeated checking of blood glucose levels and several injections of insulin throughout the day. Major drawbacks of such treatment were the need to draw blood and test glucose levels throughout the day, improper or low dosage amounts of insulin, contamination of the insulin delivery system, or lifestyle restriction. Low dosages of insulin over an extended period may cause heart disease, stroke, kidney failure, hypertension, or retinal damage.
Diabetes may be controlled by insulin replacement therapy in which insulin is delivered to the diabetic person, usually by injection, to counteract elevated blood glucose levels. Recent therapies include the basal/bolus method of treatment in which basal, a long acting insulin medication, for example, Humalog® and Apidra®, is delivered via injection once every day. The basal provides the body with a relatively constant dose of insulin throughout the day. At mealtime, an additional dose of insulin, or bolus, is administered based on the amount of carbohydrate and protein in the meal. Accurate calculations of various parameters including the amount of carbohydrates and proteins consumed, and the lapse in time since the last dosage are necessary to determine the appropriate dosage of insulin. The dosages are thus prone to human error and the method is ineffective when doses are skipped, forgotten or miscalculated. Exercise, stress and other factors can also cause the calculations to be inaccurate.
To address these problems, programmable insulin delivery devices or pumps were developed which seek to mimic the way a normal, healthy pancreas delivers insulin to the body. Insulin pumps are programmed to deliver a continual basal dose of insulin and occasionally a bolus dose in response to a patient's meal intake and physical activities. Additionally, the number of times a patient is required to draw blood and test their glucose during the day is reduced, thus lessening the pain and inconvenience of this disease.
Conventional insulin pumps are worn on the body and are connected to a patient via a cannula that is inserted somewhere on the patient's abdomen. The insulin is delivered under the skin and is absorbed into the body through the subcutaneous fat layer. Insulin pumps in the past have been quite large, some requiring the use of a shoulder bag to transport. Over time, they have become smaller in size and most pumps today are roughly the size of a deck of cards. Currently available insulin pumps include Animas OneTouch®Ping®, Deltec Cozmo®, Disetronic Accu-Chek Spirit®, Insulet OmniPod, Medtronic Paradigm™, Sooil USA DiabecareII, and Nipro Amigo®.
With the decreased size of the pump unit also comes a decreased size in the medication reservoir. This reduced reservoir size means more frequent refilling, greater potential for contamination of the reservoir, more frequent changes of the cannula and tubing, and greater expense overall in treating the condition. Recent medical data suggests that a combination of insulin and another medication, such as glucagon, infused at different times or simultaneously, leads to better results in patients.
Therefore, the need exists for a low-cost cartridge system, capable of working in tandem with a pump driver system, that contains a plurality of reservoirs for the delivery of more than one drug.
The present invention overcomes the disadvantages of the prior art and fulfills the needs noted above by providing a drug delivery device having a pump driver system, and a cartridge system.
More specifically, the present invention includes a cartridge system having a plurality of reservoirs each with volume, preferably, of 1.5 ml. Each of the plurality of reservoirs can be pre-filled with different medicaments. A pump membrane is placed between two gold-plated neodymium-iron-boron disk magnets that are each housed within a pump body insert. Each of the pump body inserts has a fluid receiving opening, a fluid discharge opening, a plurality of inlet channels, and a plurality of outlet channels. The pump body inserts are placed between two inlet/outlet members. Each of the inlet/outlet members has a fluid receiving opening, a fluid discharge opening, and a fluid outlet component. Additionally, each of the inlet/outlet members has a male part that securely engages to a female part of the reservoir forming an airtight seal. The reservoir, the fluid receiving opening of the inlet/outlet member, the fluid receiving opening, the plurality of inlet channels, the plurality of outlet channels, and the fluid discharge opening of the pump body insert, the fluid discharge opening and the fluid outlet component of the inlet/outlet member are in fluid communication. The cartridge system further includes valve membranes that are placed between the fluid receiving openings of the pump body inserts and the inlet/outlet members, and between the fluid discharge openings of the pump body inserts and the inlet/outlet members.
The valve membranes of the cartridge system can be pre-stressed and formed, for example, of Silastic Q7-4840. The reservoirs can be formed, for example, of Silastic Q7-4840, or Medical Grade Polyisoprene. The pump body inserts and the inlet/outlet members can be formed, for example, of clear polypropylene homopolymer. The pump membrane can be formed, for example, of Silastic Q7-4840.
The present invention also includes a cartridge system having a plurality of orifices to fill or re-fill a plurality of medicaments in the reservoirs. The plurality of orifices can be located on the reservoirs, or on the inlet/outlet members and the plurality of orifices are in fluid communication with the reservoirs.
The present invention further includes a method of delivering medicament using a drug delivery device having a cartridge system. The method includes the steps of providing a drug delivery device having a pump driver system and a cartridge system, loading a plurality of pre-filled reservoirs containing fluid medicament to the cartridge system, engaging securely the cartridge system and the pump driver system, selecting various parameters on a user interface of the pump driver system including selecting pre-determined values or specifying user-defined values for the parameters, and connecting an infusion set to the drug delivery device.
The method of delivering medicament using the drug delivery device includes the additional steps of placing an inset of the infusion set on a body part of a patient, attaching the infusion set to the patient's body, and switching on the drug delivery device.
The method of delivering medicament using the drug delivery device wherein the step of connecting an infusion set to the drug delivery device further includes the steps of connecting one end of a Y-catheter to an outlet component of an inlet/outlet member, and delivering fluid medicament at a given rate. The step of delivering fluid medicament at a given rate can further include delivering fluid medicament at a controlled and continuous rate for a pre-determined or user-defined period of time. Alternatively, the step of delivering fluid medicament at a given rate can further include delivering fluid medicament at a programmable rate that is regulated by the patient.
The present invention also includes a method of delivering medicament using the drug delivery device having the cartridge system. The method includes the steps of providing a drug delivery device having a pump driver system and a cartridge system, loading a plurality of reservoirs to the cartridge system, using an instrument to inject a plurality of fluid medicaments into the plurality of reservoirs, engaging securely the cartridge system and the pump driver system, selecting various parameters on a user interface of the pump driver system including selecting pre-determined values or specifying user-defined values for the parameters, and connecting an infusion set to the drug delivery device. The step of connecting an infusion set to the drug delivery device further includes the steps of connecting one end of a Y-catheter to an outlet component of an inlet/outlet member, and delivering fluid medicament at a given rate. The step of delivering fluid medicament at a given rate can further include delivering fluid medicament at a controlled and continuous rate for a pre-determined or user-defined period of time. Alternatively, the step of delivering fluid medicament at a given rate can further include delivering fluid medicament at a programmable rate that is regulated by the patient.
The present invention further includes a drug delivery device having a pump driver system, a cartridge system, a cannula and an insertion mechanism, and a plurality of conduits. The pump driver system includes a driver that drives the magnets that applies a force to the pump membrane of the cartridge system, a controller in communication with the pump to adjust the force applied by the driver, a power source, and a user interface configured to present information to a user. The cartridge system of the device snaps into the pump driver system and is securely engaged to it. The plurality of conduits each includes a proximal end, a distal end, and a lumen extending from its proximal end to its distal end. The proximal ends of the plurality of conduits are securely engaged to the distal ends of the cannula and the insertion mechanism, and the distal ends are securely engaged to the proximal ends of the fluid outlet component of the inlet/outlet members of the cartridge system.
Other features and advantages of the present invention will become apparent from the following description of the invention, which refers to the accompanying drawings.
Disclosed embodiments relate to a cartridge system for delivery of medicament and a drug delivery device containing the same.
The term “fluid” is defined as a state of matter or substance (liquid or gas) whose particles can move about freely, and has no fixed shape or conform to the shape of their containers.
The term “channel” is defined as a passage for fluids to flow through.
The term “medicament” is defined as a substance used in therapy, a substance that treats, prevents or alleviates the symptoms of disease, a medicine in a specified formulation, or an agent that promotes recovery from injury or ailment.
Referring now to the drawings, where like elements are designated by like reference numerals,
Referring to
The advantages of using polymer materials to make the reservoirs 200a, 200b, pump body inserts 300a, 300b, inlet/outlet members 700a, 700b, and any housing portion is that they can be made in any size, designed in any way and manufactured with biocompatible materials. The polymer reservoirs allow better use of the interior volume available within the pump body, and the collapsible nature of the material allows for more innovative methods for withdrawing the liquid contents. The methods used in the manufacture of the polymer components as well as the arrangement and design of the cartridge system lends itself to being readily adaptable to commonly used sterilization techniques such as gamma irradiation, steam sterilization, or fluidic chemical sterilization.
The reservoir 200a has a substantially symmetrical body having a top end (not shown), a bottom end (not shown), an inner wall 204, and an outer wall 202. The top end of the reservoir 200a has an opening 203 that is encircled by the inner wall 204 and the outer wall 202. At the top end, the inner wall 204 and the outer wall 202 project in an upward direction to form a female part 201. The female part 201 is preferably of length about 0.42 inches. The female part 201 is securely engaged to a male part 702 (
The thickness of the reservoir 200a is preferably between 50μ and 200μ. The top end, the bottom end, the inner wall 204 and the outer wall 202 enclose a reservoir space for storage of fluid medicament. The reservoirs 200a, 200b of the cartridge system 100 are preferably dual reservoir, pre-filled with fluid medicaments, each of the reservoirs 200a, 200b capable of holding 1.5 ml of fluid medicament. Although
In another preferred embodiment of the invention, the reservoirs 200a, 200b can be any free-form shaped body. The reservoirs 200a, 200b can be mounted within a reservoir shell 206, the inside of the reservoir shell 206 having an insulation layer 205.
In yet another preferred embodiment of the invention, as shown in
In yet another preferred embodiment of the invention, as shown in
It is to be understood that the reservoirs 200a, 200b mounted within a reservoir shell 206 having an insulation layer 205 or without the reservoir shell 206 can include a cap for removably closing the opening 203. The reservoirs may be designed to work with any drug delivery device for delivery of medicaments.
Referring to
The second pump body insert 300b, shown in
The cartridge system 100 has a pump membrane 400 as shown in
Referring to
The second inlet/outlet member 700b, shown in
The male part 702 of the inlet/outlet members 700a, 700b can have tooth-like channels to ensure that a low resistance path for fluid flow exists for all configurations of the reservoirs 200a, 200b. The reservoirs 200a, 200b, the pump body inserts 300a, 300b, the pump membrane 400, and the inlet/outlet members 700a, 700b are securely engaged using housing units 800a, 800b, 800c shown in
Four valve membranes 600, shown in
When cartridge system 100 is assembled together, the first reservoir 200a, the fluid receiving opening 704 of the first inlet/outlet member 700a, the fluid receiving opening 301 of the first pump body insert 300a, the plurality of inlet channels 308a and the plurality of outlet channels 307a, 307b of the first pump body insert 300a, the fluid discharge opening 302 of the first pump body insert 300a, and the fluid discharge opening 703 and the fluid outlet component 701 of the first inlet/outlet member 700a are in fluid connection. Likewise, the second reservoir 200b, the fluid receiving opening 704 of the second inlet/outlet member 700b, the fluid receiving opening 301 of the second pump body insert 300b, the plurality of inlet channels 308a, 308b and the plurality of outlet channels 307a of the second pump body insert 300b, the fluid discharge opening 302 of the second pump body insert 300b, and the fluid discharge opening 703 and the fluid outlet component 701 of the second inlet/outlet member 700b are in fluid connection.
In another embodiment of the present invention, a system 900 is shown in
Referring to
Referring to
A diabetic patient can use the drug delivery device 1000 along with the accessories 1101, 1102 shown in
The step of connecting an infusion set to the drug delivery device can include connecting the distal ends of a Y-catheter to the luer slips of the fluid outlet component of the inlet/outlet members. Subsequently, the patient user can place an inset of the infusion set on a body part of the patient, attach the infusion set to the body, and switch on the drug delivery device. When the patient user uses only one reservoir in the cartridge system, the step of connecting an infusion set to the drug delivery device can include connecting the distal end of the Y-catheter to the luer slip of the outlet component of the inlet/outlet member.
The delivery of medicaments can be at a controlled and continuous rate for a pre-determined or user-defined period of time. Alternatively, the delivery of medicament can also be at a programmable rate that is regulated by the patient. The drug delivery device can be preprogrammed to infuse medicaments at a constant basal rate or variable bolus rate over a certain period of time. The device can deliver micro-doses of medicaments—insulin, glucagon or other medication—at controlled and continuous rate for a pre-determined period of time.
In another method of delivering medicament using the drug delivery device 1000 having the cartridge system 100, a drug delivery device 1000 having a pump driver system 1001 and a cartridge system 100 is provided to the patient user. A plurality of reservoirs 200a, 200b are loaded to the cartridge system 100 and the reservoirs 200a, 200b are filled with medicaments using an instruments, for example, a syringe. The cartridge system 100 is then snapped into and securely engaged to the pump driver system 1001. The user then selects various parameters on a user interface on the pump driver system 1001. These parameters can include, but not be limited to, basal rate, insulin amount, bolus rate based on the calories of carbohydrates, protein, fat or fiber consumed, and the blood glucose level including the actual and target glucose levels. The user can either select pre-determined values or specify user-defined values for each of the parameters. The user connects an infusion set having accessories 1101, 1102 to the drug delivery device 1000. Subsequently, the patient user can place an inset of the infusion set on a body part of the patient, attach the infusion set to the body, and switch on the drug delivery device.
While the present invention is described herein with reference to illustrative embodiments for particular applications, it should be understood that the invention is not limited thereto. Those having ordinary skill in the art and access to the teachings provided herein will recognize additional modifications, applications, embodiments and substitution of equivalents all fall within the scope of the invention. Accordingly, the invention is not to be considered as limited by the foregoing description.
This application is a continuation of and claims priority to U.S. Nonprovisional Patent Application Ser. No. 13/308,899, filed Dec. 1, 2011 (now U.S. Pat. No. 8,771,229, granted Jul. 8, 2014), and titled “CARTRIDGE SYSTEM FOR DELIVERY OF MEDICAMENT”, the entire contents of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
2398435 | Marks | Apr 1946 | A |
3137242 | Hahn | Jun 1964 | A |
3498228 | Blumle et al. | Mar 1970 | A |
3691263 | Stoy et al. | Sep 1972 | A |
3771694 | Kaminski | Nov 1973 | A |
3827565 | Matsumura | Aug 1974 | A |
3889710 | Brost | Jun 1975 | A |
3915609 | Robinson | Oct 1975 | A |
4017238 | Robinson | Apr 1977 | A |
4197266 | Clark et al. | Apr 1980 | A |
4257416 | Prager | Mar 1981 | A |
4340048 | Eckenhoff | Jul 1982 | A |
4376618 | Toyoda et al. | Mar 1983 | A |
4415003 | Paradis et al. | Nov 1983 | A |
4498843 | Schneider et al. | Feb 1985 | A |
4544369 | Skakoon et al. | Oct 1985 | A |
4552561 | Eckenhoff et al. | Nov 1985 | A |
4657486 | Stempfle et al. | Apr 1987 | A |
4712583 | Pelmulder et al. | Dec 1987 | A |
4731726 | Allen, III | Mar 1988 | A |
4784644 | Sawyer et al. | Nov 1988 | A |
4797144 | DeMeritt et al. | Jan 1989 | A |
4840754 | Brown et al. | Jun 1989 | A |
4936833 | Sams | Jun 1990 | A |
4938742 | Smits | Jul 1990 | A |
4946448 | Richmond | Aug 1990 | A |
4947856 | Beard | Aug 1990 | A |
4958661 | Holtermann et al. | Sep 1990 | A |
4966199 | Ruschke | Oct 1990 | A |
5019974 | Beckers | May 1991 | A |
5050612 | Matsumura | Sep 1991 | A |
5147323 | Haber et al. | Sep 1992 | A |
5218993 | Steinberg et al. | Jun 1993 | A |
5246634 | Ichikawa et al. | Sep 1993 | A |
5370635 | Strausak et al. | Dec 1994 | A |
5584815 | Pawelka et al. | Dec 1996 | A |
5645855 | Lorenz | Jul 1997 | A |
5674557 | Wildman et al. | Oct 1997 | A |
5709662 | Olive et al. | Jan 1998 | A |
5762632 | Whisson | Jun 1998 | A |
5775671 | Cote, Sr. | Jul 1998 | A |
5822715 | Worthington et al. | Oct 1998 | A |
5858001 | Tsals et al. | Jan 1999 | A |
6003736 | Ljunggren | Dec 1999 | A |
6017331 | Watts et al. | Jan 2000 | A |
6056718 | Funderburk et al. | May 2000 | A |
6305661 | Kennedy | Oct 2001 | B1 |
6311712 | Meyer | Nov 2001 | B1 |
6315929 | Ishihara et al. | Nov 2001 | B1 |
6390120 | Guala | May 2002 | B1 |
6409707 | Guala | Jun 2002 | B1 |
6572586 | Wojcik | Jun 2003 | B1 |
6627124 | Herbrechtsmeier et al. | Sep 2003 | B1 |
6648859 | Bitdinger et al. | Nov 2003 | B2 |
6723086 | Bassuk et al. | Apr 2004 | B2 |
6813906 | Hirota et al. | Nov 2004 | B1 |
6945963 | Langley et al. | Sep 2005 | B2 |
7044125 | Vedrine et al. | May 2006 | B2 |
7061108 | Wright et al. | Jun 2006 | B2 |
7104973 | Woolston et al. | Sep 2006 | B2 |
7123985 | Wildsmith et al. | Oct 2006 | B2 |
7296782 | Enerson et al. | Nov 2007 | B2 |
7302311 | Varis | Nov 2007 | B2 |
7407490 | Bendsen et al. | Aug 2008 | B2 |
7470265 | Massengale | Dec 2008 | B2 |
7510544 | Vilks et al. | Mar 2009 | B2 |
7537590 | Santini, Jr. et al. | May 2009 | B2 |
7585167 | Lawton et al. | Sep 2009 | B2 |
7637899 | Woolston et al. | Dec 2009 | B2 |
7846146 | Woolston et al. | Dec 2010 | B2 |
7850663 | Sullivan et al. | Dec 2010 | B2 |
7896002 | Watanabe | Mar 2011 | B2 |
7914499 | Gonnelli et al. | Mar 2011 | B2 |
7935280 | Lawton et al. | May 2011 | B2 |
7967795 | Cabiri | Jun 2011 | B1 |
8021334 | Shekalim | Sep 2011 | B2 |
8663538 | Amirouche et al. | Mar 2014 | B2 |
8764425 | Amirouche et al. | Jul 2014 | B2 |
8771229 | Amirouche | Jul 2014 | B2 |
8790307 | Amirouche | Jul 2014 | B2 |
8807169 | Amirouche et al. | Aug 2014 | B2 |
20020119711 | VanAntwerp et al. | Aug 2002 | A1 |
20030100883 | Kristensen et al. | May 2003 | A1 |
20030180164 | Bunner et al. | Sep 2003 | A1 |
20040050104 | Ghosh et al. | Mar 2004 | A1 |
20040176727 | Shekalim | Sep 2004 | A1 |
20050065500 | Couvillon, Jr. et al. | Mar 2005 | A1 |
20050192557 | Brauker et al. | Sep 2005 | A1 |
20060021386 | Wang | Feb 2006 | A1 |
20060073232 | Wang | Apr 2006 | A1 |
20060145372 | Jones et al. | Jul 2006 | A1 |
20060224109 | Steil et al. | Oct 2006 | A1 |
20070073230 | Jasperson et al. | Mar 2007 | A1 |
20070087068 | Eiha et al. | Apr 2007 | A1 |
20070225147 | Hayashi et al. | Sep 2007 | A1 |
20070233008 | Kristensen et al. | Oct 2007 | A1 |
20070299398 | Alferness et al. | Dec 2007 | A1 |
20080169444 | Guala | Jul 2008 | A1 |
20090062767 | Van Antwerp et al. | Mar 2009 | A1 |
20090069650 | Jennewine | Mar 2009 | A1 |
20090105658 | Jennewine | Apr 2009 | A1 |
20100004603 | Kristensen et al. | Jan 2010 | A1 |
20100081993 | O'Connor | Apr 2010 | A1 |
20100100077 | Rush et al. | Apr 2010 | A1 |
20100185322 | Bylsma et al. | Jul 2010 | A1 |
20100225013 | Eiha et al. | Sep 2010 | A1 |
20100241086 | Yodfat et al. | Sep 2010 | A1 |
20100255366 | Myland | Oct 2010 | A1 |
20100256593 | Yodfat et al. | Oct 2010 | A1 |
20100280461 | Forstreuter | Nov 2010 | A1 |
20100317093 | Turewicz et al. | Dec 2010 | A1 |
20110021905 | Patrick et al. | Jan 2011 | A1 |
20110066131 | Cabiri | Mar 2011 | A1 |
20110114744 | Ricciardi et al. | May 2011 | A1 |
20110118675 | Miller et al. | May 2011 | A1 |
20110137287 | Gonnelli et al. | Jun 2011 | A1 |
20110160696 | Hoss | Jun 2011 | A1 |
20110168294 | Jakobsen et al. | Jul 2011 | A1 |
20110251546 | Sullivan et al. | Oct 2011 | A1 |
20110274566 | Amirouche | Nov 2011 | A1 |
20110308650 | Amirouche et al. | Dec 2011 | A1 |
20110309229 | Amirouche et al. | Dec 2011 | A1 |
20110309552 | Amirouche et al. | Dec 2011 | A1 |
20120002422 | Lia et al. | Jan 2012 | A1 |
20120053571 | Petri | Mar 2012 | A1 |
20130144254 | Amirouche et al. | Jun 2013 | A1 |
20130237947 | Amirouche et al. | Sep 2013 | A1 |
20130274576 | Amirouche et al. | Oct 2013 | A1 |
20130274577 | Amirouche et al. | Oct 2013 | A1 |
20130345650 | Amirouche | Dec 2013 | A1 |
20140155819 | Amirouche et al. | Jun 2014 | A1 |
Number | Date | Country |
---|---|---|
0 024 431 | Aug 1985 | EA |
0 299 628 | Jan 1989 | EP |
2 248 891 | Apr 1992 | GB |
62-297120 | Dec 1987 | JP |
2007-015906 | Jan 2007 | JP |
2007-0119280 | May 2007 | JP |
2008-96089 | Apr 2008 | JP |
WO 03047426 | Jun 2003 | WO |
WO 2004067964 | Aug 2004 | WO |
WO 2006111775 | Oct 2006 | WO |
WO 2007055642 | May 2007 | WO |
20 2009048462 | Apr 2009 | WO |
WO 2010128914 | Nov 2010 | WO |
Entry |
---|
International Search Report and Written Opinion issued in International Patent Application No. PCT/US2013/072787, dated Apr. 24, 2014 (9 pages). |
U.S. Appl. No. 13/174,598, filed Jun. 30, 2011, by Amirouche et al.: Notice of Allowance, dated Apr. 7, 2014. |
U.S. Appl. No. 13/174,624, filed Jun. 30, 2011 by Amirouche et al.: Notice of Allowance, dated Feb. 5, 2014. |
U.S. Appl. No. 13/308,899, filed Dec. 1, 2011, by Amirouche et al.: Notice of Allowance, dated Feb. 28, 2014. |
U.S. Appl. No. 13/370,091, filed Feb. 9, 2012, by Amirouche et al.: Notice of Allowance, dated Mar. 25, 2014. |
“Bartels micropumps,” Apr. 2009, [online] http://www.bartelsmikrotechnik.de/index.php/micropumps.html. |
“Diabetes Basics: Diabetes Statistics,” American Diabetes Association, [Online]. Available at: http://www.diabetes.org/diabetes-basics/. [Accessed May 14, 2012] (3 pages). |
“Diabetic Neuropathy, Living With Numbness and Pain,” A Diabetic Life, [Online]. Available at: http://www.a-diabetic-life.com/diabetic-neuropathy.html. [Accessed May 5, 2012] (3 pages). |
“Electromyogram (EMG),” MedicineNet.com, [Online]. Available at: http://www.medicinenet.com/electromyogram/article.htm. [Accessed May 15, 2012] (3 pages). |
“Nerve conduction velocity,” MedlinePlus®, A Service of the U.S. National Library of Medicine, National Institutes of Health, [Online]. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/003927.htm; updated Jun. 18, 2011 (3 pages). |
“Peripheral Neuropathy Fact Sheet,” National Institue of Neurological Disorders and Stroke, NIH Publication No. 04-4853, [Online]. Available: http://www.ninds.nih.gov/disorders/peripheralneuropathy/detail_peripheralneuropathy.htm; updated Sep. 19, 2012 (9 pages). |
“Peripheral Neuropathy Market Approaches US$1B by 2012,” PR Newswire, United Business Media [Online]. Available at: http://www.prnewswire.co.uk/news-releases/peripheral-neuropathymarket-approaches-us1b-by-2012-154534705.html. Apr. 7, 2012 (2 pages). |
“Silastic® BioMedical Grade ETR elastomers”, Dow Corning, 2002-2011, accessed at http://www4.downcorning.com/DataFiles/090007c88028669a.pdf (5 pages). |
“Silastic® Biomedical Grade Liquid Silicone Rubers”, Down Corning, 2006, accessed at http://www4.dowcorning.com/DataFiles/090007c88097f96.pdf (6 pages). |
“Small, powerful, light, precise: micro diaphragm pumps made of plastics: thinXXS micropumps” Mar. 2009, [online] http://www.thinxxs. com/main/produkte/micropumps.html (2 pages). |
“Sylgard® 164 Silicone Elastomer”, Dow Corning, 2007, accessed at http://ncnc.engineering.ucdavis.edu/pages/equipment/Sylgard_164_data_sheet.pdf (3 pages). |
Acevedo, “Creation of Dual Chamber Micropump Using Rapid Prototyping,” Milwaukee School of Engineering, Research Experience for Undergraduates Paper, 2005. Available online at: http://www.msoe.edu/academics/research_centers/reu/pdf/2005/Creation%20of%20a%20Dual%20Chamber%20Micropump%20using%20Rapid%20Prototyping.pdf (6 pages). |
Amirouche et al., “Current Micropump Technologies and Their Biomedical Applications,” Microsystem Technology, 2009, pp. 647-666, vol. 15. |
Anhalt et al., “Insulin Patch Pumps: Their Development and Future in Closed-Loop Systems,” Diabetes Technology & Therapeutics, 2010, pp. 51-58, vol. 12. |
Bak et al., “Multiple Insulin Injections Using a Pen Injector Versus Insulin Pump Treatment in Young Diabetic Patients,” Diabetes Research, 1987, pp. 155-158, vol. 6. |
Barbano et al., “Effectiveness, Tolerability, and Impact on Quality of Life of the 5% Lidocaine Patch in Diabetic Polyneuropathy,” Archives of Neurology, 2004, pp. 914-918, vol. 61, No. 6. |
Bohm et al., “A plastic micropump constructed with conventional techniques and materials,” Sensors and Actuators A, vol. 77-3, pp. 223-228, 1999. |
Casella et al., “Accuracy and Precision of Low-Dose Insulin Administration,” Pediatrics, 1993, pp. 1155-1157, vol. 91. |
Dario et al., “A fluid handling system for a chemical microanalyzer,” J. Micromech. Microeng., vol. 6, pp. 95-98, 1996. |
Davis et al., “Techniques for Improved Soft Lens Fitting”; Aug. 1, 2005, p. 2, accessed at http://www.cispectrum.com/articleviewer.aspx?articleid=12852 (5 pages). |
Einhorn et al., “Advances in Diabetes for the Millennium: Insulin Treatment and Glucose Monitoring,” Medscape General Medicine, 2004, p. 8, vol. 6, (3 Suppl.) [Online]. Available at: http://www.medscape.org/viewarticle/488996 (9 pages). |
Elleri et al., “Closed-Loop Insulin Delivery for Treatment of Type 1 Diabetes,” BMC Medical, 2011, p. 120, vol. 9 [Online]. Available at: http://www.biomedcentral.com/1741-7015/9/120 (9 pages). |
Farnbach, “Peripheral Nerve Testing and Electromyography,” [Online]. Available at: http://cal.vet.upenn.edu/projects/saortho/appendix_d/appd.htm. [Accessed May 18, 2012] (10 pages). |
Fu et al. “TiNi-based thin films in MEMS applications: a review,” Sensors and Actuators A, 2004, pp. 3950408, vol. 112, No. 23. |
Galer et al., “The Lidocaine Patch 5% Effectively Treats All Neuropathic Pain Qualities: Results of a Randomized, Double-Blind, Vehicle-Controlled, 3-Week Efficacy Study with Use of the Neuropathic Pain Scale,” The Clinical Journal of Pain, 2002, pp. 297-301, vol. 18, No. 5 (Abstract). |
Gammaitoni et al., “Pharmacokinetics and Tolerability of Lidocaine Patch 5% with Extended Dosing,” The Annals of Pharmacotherapy, 2002, pp. 236-240, vol. 36, No. 2, (Abstract). |
Ha et al., “Disposable thermo-pneumatic micropump for bio lab-on-a-chip application,” Microelectronic Engineering, 2009, pp. 1337-1339, vol. 86. |
Ignaut et al., “Comparative Device Assessments: Humalog KwikPen Compared with Vial and Syringe and FlexPen,” The Diabetes Educator, 2009, pp. 789-798, vol. 35, No. 2. |
International Search Report and Written Opinion issued in International Patent Application No. PCT/US2009/059020, dated Mar. 9, 2010 (17 pages). |
International Search Report and Written Opinion issued in PCT International Application No. PCT/US2012/066937, dated Mar. 7, 2013 (9 pages). |
International Search Report and Written Opinion issued in International Patent Application No. PCT/US2013/035918, dated Jun. 21, 2013 (9 pages). |
International Search Report and Written Opinion issued in International Patent Application No. PCT/US2013/035921, dated Jul. 1, 2013 (11 pages). |
International Search Report and Written Opinion issued in International Patent Application No. PCT/US0213/046546, dated Aug. 8, 2013 (11 pages). |
Irawan et al., “Fabrication and performance testing of disposable micropump suitable for microfluidic chip,” in Intl. Conf. on Biomedical and Pharmaceutical Engineering, Orchard Hotel, Singapore, Dec. 2006, 252-255. |
Jeong, et al. “Fabrication of a peristaltic PDMS micropump,” Sensors and Actuators A, vol. 123-124, pp. 453-458, 2005. |
Junwu et al., “Design and test of a high-performance piezoelectric micropump for drug delivery,” Sensors and Actuators A, vol. 121, pp. 156-161, 2005. |
Klonoff et al., “Insulin Pump Safety Meeting: Summary Report,” Journal of Diabetes Science and Technology, 2009, pp. 396,402, vol. 3, No. 2. |
Koch, et al., “PDMS and tubing-based peristaltic micropumps with direct actuation,” Sensors and Actuators B, vol. 135, pp. 664-670, 2009. |
Laser et al., “A review of micropumps,” J. Micromech. Microeng., vol. 14(6), pp. R35-R64, 2004. |
Lee et al., “Microfluidic mixing: A review,” Int. J. Mol. Sci., 2011, pp. 3263-3287, vol. 12. |
Li et al., “A high frequency high flow rate piezoelectrically driven MEMS micropump” in Proceedings IEEE Solid State Sensors and Actuators Workshop, Hilton Head, SC, Jun. 2000 (4 pages). |
Ma et al., “Development and application of a diaphragm micro-pump with piezoelectric device,” Microsyst. Technol., vol. 14, pp. 1001-1007, 2008. |
Manz, et al., “Miniaturized total chemical analysis systems: a novel concept for chemical sensing,” Sensors and Actuators B, vol. 1, pp. 244-248, 1990. |
Meece et al., “Effect of Insulin Pen Devices on the Management of Diabetes Mellitus,” Am J Health-Syst. Pharm., 2008, pp. 1076-1082, vol. 65. |
Melin et al., “A fast passive and planar liquid sample micromixer,” Lab on a Chip, 2004, pp. 214-219, vol. 4. |
Morrow, “Transdermal Patches Are More Than Skin Deep,” Managed Care [Online]. Available at: http://www.managedcaremag.com/archives/0404/0404.biotech.html. Apr. 2004 (4 pages). |
Mundell, “Antidepressant Cymbalta Might Ease Chemo-Linked Pain,” MSN Healthy Living, 2013 [Online]. Available at: http://health.msn.com/health-topics/cancer/antidepressant-cymbalta-might-ease-chemo-linked-pain (4 pages). |
Nguyen et al., “MEMS-micropumps: A review,” Journal of Fluids Engineering, vol. 124, p. 384-392, 2002. |
Nguyen et al., “Microfluidics for Internal Flow Control: Micropumps,” in Fundamentals and Applications of Microfluidics. Norwood, MA: Artech House, Inc., 2002; pp. 293-341. |
Nisar et al., “MEMS-based Micropumps in Drug Delivery and Biomedical Applications,” Sensors and Actuators B, 2006, pp. 917-942, vol. 130. |
Pallikaris, “Intracorneal mico-lens a minimally invasive option for presbyopia”; Aug. 10, 2010, p. 1, paragraph 003, accessed at http://www.rigneygraphics.com/clients/presbia/website/newsmedia/pdfs/press-osn-presbia.pdf (2 pages). |
Pan et al., “A magnetically driven PDMS micropump with ball check-valves,” J. Micromech. Microeng. vol. 15, pp. 1021-1026, 2005. |
Rapp et al., “Liga micropump for gases and liquids,” Sensors and Actuators A, 1994, pp. 57-61, vol. 40, No. 1. |
Richardson et al., “Peripheral Neuropathy: A True Risk Factor for Falls,” The Journal of Gerontology: Series A, 1995, pp. 211-215, vol. 50, No. 4 (Abstract). |
Roberts, “Blind Attack on Wireless Insulin Pumps Could Deliver Lethal Dose,” Threatpost.com, The Kaspersky Lab Security News Service, Oct. 27, 2011 (2 pages). |
Rosielle, “The Lidocaine Patch,” Medical College of Wisconsin [Online]. Available: http://www.eperc.mcw.edu/EPERC/FastFactsindex/ff_146.htm. [Accessed May 15, 2012] (3 pages). |
Santra et al., “Fabrication and testing of a magnetically actuated micropump,” Sensors and Actuators B, vol. 87, pp. 356-364, 2002. |
Selam, “Evolution of Diabetes Insulin Delivery Devices,” Journal of Diabetes Science and Technology, 2010, pp. 505-513, vol. 4, No. 3. |
Shen et al., “Miniaturized PMMA ball-valve with micropump with cylindrical electromagnetic actuator,” Microelectronic Engineering, vol. 85, pp. 1104-1107, 2008. |
Singhal, et al., “Microscale pumping technologies for microchannel cooling systems,” Appl. Mech. Rev., vol. 57(3), pp. 191-221, 2004. |
Star Micronics Co. Ltd., “Precision products,” Mar. 2009, [online]. Accessed at: http://www.star-m.jp/eng/products/precision/index/html, on Aug. 22, 2011 (4 pages). |
Trenkle et al., “Normally-closed peristaltic micropump with re-usable actuator and disposable fluidic chip,” Sensors and Actuators B, vol. 154, pp. 137-141, 2011. |
Tsai et al., “Review of MEMS-based drug delivery and dosing systems,” Sensors and Actuators A, vol. 134, No. 2, pp. 555-564, 2007. |
U.S. Appl. No. 13/174,598, filed Jun. 30, 2011, by Amirouche et al.: Non-Final Rejection, dated May 14, 2013. |
U.S. Appl. No. 13/174,598, filed Jun. 30, 2011, by Amirouche et al.: Final Rejection, dated Oct. 3, 2013. |
U.S. Appl. No. 13/174,624, filed Jun. 30, 2011 by Amirouche et al.: Non-Final Rejection, dated Jun. 28, 2012. |
U.S. Appl. No. 13/174,624, filed Jun. 30, 2011 by Amirouche et al.: Final Rejection, dated Nov. 21, 2012. |
U.S. Appl. No. 13/174,624, filed Jun. 30, 2011 by Amirouche et al.: Non-Final Rejection, dated Feb. 8, 2013. |
U.S. Appl. No. 13/174,624, filed Jun. 30, 2011 by Amirouche et al.: Final Rejection, dated Jul. 31, 2013. |
U.S. Appl. No. 13/174,643, filed Jun. 30, 2011 by Amirouche et al.: Non-Final Rejection, dated May 2, 2013. |
U.S. Appl. No. 13/174,643, filed Jun. 30, 2011 by Amirouche et al.: Notice of Allowance, dated Oct. 21, 2013. |
U.S. Appl. No. 13/308,899, filed Dec. 1, 2011 by Amirouche et al.: Non-Final Rejection, dated Aug. 8, 2013. |
U.S. Appl. No. 13/370,091, filed Feb. 9, 2012, by Amirouche et al.: Non-Final Rejection, dated Aug. 21, 2013. |
U.S. Appl. No. 13/649,202, filed Oct. 11, 2012, by Amirouche: Non-Final Rejection, dated Jun. 18, 2013. |
U.S. Appl. No. 13/649,202, filed Oct. 11, 2012, by Amirouche: Final Rejection, dated Jan. 20, 2014. |
U.S. Appl. No. 13/692,868, filed Dec. 3, 2012, by Amirouche et al. |
Van Lintel, et al., “A piezoelectric micropump based on micromachining of silicon,” Sensors and Actuators A, vol. 15, 153-167, 1988. |
Yadav et al., “Various Non-Injectable Delivery Systems for the Treatment of Diabetes Mellitus,” Endochrine, Metabolic & Immune Disorders-Drug Targets, 2009, pp. 1-13, vol. 9, No. 1. |
Yamahata, et al. “A PMMA valveless micropump using electromagnetic actuation.” Microfluid Nanofluid, vol. 1, pp. 197-207, 2005. |
Zhu et al., “Optimization design of multi-material micropump using finite element method,” Sensors and Actuators A, vol. 149, pp. 130-135, 2009. |
Number | Date | Country | |
---|---|---|---|
20140257350 A1 | Sep 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13308899 | Dec 2011 | US |
Child | 14288052 | US |